RVU.WA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 18:00):

Stats
Dzisiejszy wolumen	2 291.00
Średni wolumen	4 242.00
Kapitalizacja rynkowa	1.15B
EPS	PLN-0.800 ( 2023-11-29 )
Last Dividend	PLN0 ( N/A )
Next Dividend	PLN0 ( N/A )
P/E	-12.46
ATR14	PLN0.151 (0.30%)

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: 0.09 (neutral)

Signal:(41.636) Neutral

Ryvu Therapeutics S.A. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ryvu Therapeutics S.A. Korelacja - Waluta/Towar

0.82
( strong )

0.75
( moderate )

0.69
( moderate )

-0.33
( neutral )

0.56
( weak )

-0.10
( neutral )

Ryvu Therapeutics S.A. Finanse

Annual	2023
Przychody:	PLN46.86M
Zysk brutto:	PLN-113.44M (-242.09 %)
EPS:	PLN-4.02

FY	2023
Przychody:	PLN46.86M
Zysk brutto:	PLN-113.44M (-242.09 %)
EPS:	PLN-4.02

FY	2022
Przychody:	PLN38.80M
Zysk brutto:	PLN21.40M (55.14 %)
EPS:	PLN-4.57

FY	2021
Przychody:	PLN11.19M
Zysk brutto:	PLN-2.54M (-22.69 %)
EPS:	PLN-0.965

Financial Reports:

No articles found.

Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.